Wednesday, November 30, 2016
Positive interim results reached from the Phase 2b clinical study of its lead product, oregovomab, in patients with advanced epithelial ovarian, adnexal or peritoneal carcinoma.
Quest PharmaTech Launches Scientifically Proven, Clinically Validated Premium Skin Care Cosmetics in Canada
Quest announce the commercial launch of the Bellus Skin line of premium cosmetic products in Canada on November 17.
The Alberta Export Awards are the province’s most prestigious awards, paying tribute to the success and innovative approaches of Alberta export companies. NanoSpeed is a finalist for the Advanced Technology and Innovation.
OncoVent Initiates Clinical Development Program for Anti-MUC1 MAb AR20.5 for Treatment of Pancreatic Cancer
Signed Agreement with Cell Culture Company (C3) for Manufacturing of Clinical Grade Antibody to Support Planned Clinical Studies.
KMT Hepatech, a long-standing BioAlberta member, wins CV Magazine "Best for Health R&D Business Development - Canada."
OncoQuest Inc, a subsidiary of Edmonton-based Quest PharmaTech Inc., announce positive results from its pre-clinical pharmacology studies using its Anti-MUC1 antibody, MAb AR20.5, against pancreatic cancer in a mouse model.
Wednesday, October 5, 2016
Singularity University (SU) is offering a spot in their coveted accelerator program to innovative companies in the life sciences.
Thursday, September 29, 2016
Ceapro announce the grand opening of its new 30,000-square-foot bioprocessing extraction / manufacturing facility in Edmonton.
Quest PharmaTech Announces Filing of Restated Audited Financial Statements for the Year Ended January 31, 2016 and for the Quarter Ended April 30, 2016
Wednesday, August 10, 2016
Quest PharmaTech Inc. (TSX-V: QPT) (“Quest” or the “Company”), today announces the filing on SEDAR of restated financial statements for the year ended January 31, 2016 and for the three-month period ended April 30, 2016 and restated management discussion.
Tuesday, June 7, 2016
VaxAlta Inc. is pleased to announce a new collaboration with the Faculty of Science at the University of Alberta to advance early stage livestock vaccines research.
Tuesday, June 28, 2016
A "Point-of-Care Detection for Patients with Acute Myocardial Infarction" CHALLENGE is being launched in close collaboration with DynaLIFE Dx. Don't delay ... apply today!
BioAlberta and the life sciences Industry is thrilled that Minister Deron Bilous will lead the Alberta delegation to BIO 2016. The convention takes place in San Francisco on June 6-9.
AITF & AIHS announce new "Alberta Small Business Innovation & Research Initiative" program. This commercialization program provides SMEs with access to the supply chains of large end-users, and de-risks innovative solutions for those end-users.
Tuesday, May 31, 2016
Edmonton, May 30, 2016 – KMT Hepatech, Inc., a Canadian biotechnology company offering in vivo research services utilizing theproprietary KMT MouseTM, announced that representatives will be participating in the BIO International Convention.
Edmonton's biotech and natural medicines pioneer - Dr. Jackie Shan - today launches Canada's newest allergy medicine, Allergy-FX™
Allergy-FX™ has fighting properties of quail eggs which reduces symptoms from most common allergies and begins working within 15 minutes.
Metabolomic Technologies Inc. signs exclusive licensing and distribution agreement with U.S. based Atlantic Diagnostic Laboratories LLC.